"Value for money" in treating Alzheimer's disease with the new cholinesterase inhibitors

International Journal of Psychiatry in Clinical Practice

Volumn 7, Issue 1, 2003, Pages 45-47

  Shah, Ajit ^a   Jenkins, Rachel ^b  

^a WEST LONDON MENTAL HEALTH NHS TRUST   (United Kingdom)

^b KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

Alzheimer's disease; Dementia; Health economics

Indexed keywords

CHOLINESTERASE INHIBITOR;

ALZHEIMER DISEASE; ARTICLE; COST CONTROL; COST EFFECTIVENESS ANALYSIS; COST OF ILLNESS; DEVELOPED COUNTRY; DRUG EFFICACY; DRUG USE; HUMAN; INSTITUTIONALIZATION; NURSING HOME; PRESCRIPTION; PRIORITY JOURNAL; PROBABILITY; SOCIAL WORK;

EID: 0037357725     PISSN: 13651501     EISSN: None     Source Type: Journal    
DOI: 10.1080/13651500310001068     Document Type: Article

References (45)

1. Hu T, Huang L, Cartwright WS (1986) Evaluation of the costs of caring for the senile demented elderly: a pilot study Gerontologist 26: 158-63.
2. Hay JW, Ernst RL (1987) The economic costs of Alzheimer's disease. Am J Public Health 77: 1169-75.
3. Huang L, Cartwright WS, Hu T (1988) The economic cost of senile dementia in the United States, 1985. Public Health Rep 103: 3-7.
4. Kavanagh S, Schneider J, Knapp M et al (1992) Elderly people with cognitive impairment: costing possible changes in the balance of care. Health Soc Care 1: 69-80.
5. Gray A, Fenn P (1993) Alzheimer's disease: the burden of the illness in England. Health Trends 25: 31-7.
6. Rice DP, Fox PJ, Max W et al (1993) The economic burden of Alzheimer's disease. Health Affairs 1993: 164-76 (Summer).
7. Ernst RL, Hay JW (1994) The US economic and social costs of Alzheimer's disease revisited. Am J Public Health 84: 1261-4.
8. Ostbye T, Crosse E (1994) Net economic costs of dementia in Canada. Can Med Assoc J 151: 1457-64.
9. Smith K, Shah AQK, Wright K, Lewis G (1995) The prevalence and costs of psychiatric disorders and learning disability Br J Psychiatry 166: 9-18.
10. Souetre EJ, Qing W, Vigoureux I et al (1995) Economic analysis of Alzheimer's disease in outpatients: impact of symptom severity Int Psychogeriatr 7: 115-22.
11. Souetre E, Thwaites MA, Yeardley HL (1999) Economic impact of Alzheimer's disease in the United Kingdom. Cost of care and disease severity for non-institutionalized patients with Alzheimer's disease. Br J Psychiatry 174: 51-5.
12. Cavallo MC, Fattore G (1997) The economic and social burden of Alzheimer's disease on families in the Lombardy region of Italy Alzheimer's Dis Rel Disord 11: 184-90.
13. Wimo A, Karlsson G, Sandman PO et al (1997) Cost of illness due to dementia in Sweden. Int J Geriatr Psychiatry 12: 857-61.
14. Holmes J, Pugner K, Phillips R et al (1998) Managing Alzheimer's disease: the cost of care per patient. Br J Health Care Manage 4: 332-7.
15. Leon J, Cheng CK, Neumann PJ (1998) Alzheimer's disease care: costs and potential savings. Health Affairs 17: 206-16.
16. Andersen CK, Sogaard J, Hansen E et al (1999) The cost of dementia in Denmark: the Odense study. Dement Geriatr Cogn Disord 10: 295-304.
17. O'shea E, O'Reilly S (1977) The economic and social cost of dementia in Ireland, Int J Geriatr Psychiatry 15: 208-18.
18. Jorm AF, Korten AE, Henders AS (1987) The prevalence of dementia: a quantitative integration of the literature. Acta Psychiatr Scand 76: 465-79.
19. Hofmann A, Rocca WA, Brayne C et al (1991) The prevalence of dementia in Europe: a collaborative study of 1980-1990 findings (European collaboration). Int J Epidemiol 20: 736-40.
20. Shah AK, Ames D (1994) Planning and developing psychogeriatric services. Int Rev Psychiatry 6: 15-27.
21. Shah AK, Lindesay J. (2001) Cross-cultural issues in the assessment of cognitive impairment. In: O'Brien J, Ames D, Burns A (eds) Dementia. Arnold, London: 217-32.
22. Rothstein Z, Prohovnik I, Davidson M et al (1996) The economic burden of Alzheimer's disease in Israel. Israeli J Med Sci 32: 1120-3.
23. Welch HG, Walsh JS, Larson EB (1992) The cost of institutional care in Alzheimers disease: nursing home and hospital use in a prospective cohort. J Am Geriatr Soc 40: 221-4.
24. Stommel M, Collins CE, Given BA (1994) The costs of family contributions to the care of persons with dementia. Gerontologist 34: 199-205.
25. Philp I, McKee KJ, Meldrum P et al (1995) Community care for demented and non-demented elderly people: a comparison study of financial burden, service use, and unmet needs in family supporters. BMJ 310: 1503-6.
26. Knapp MJ, Knopman DS, Solomon PR et al (1994) A 30-week randomised controlled trial of high-dose tacrine in patients with Alzheimer's disease J Am Med Assoc 271: 985-91.
27. Rogers SL, Doody RS, Mohs RC et al (1996) The efficacy and safety of donepezil in patients with Alzheimer's disease: results of a multicentre, randomised, double-blind, placebo-controlled trial. Dementia 7: 293-303.
28. Donepezil Study Group, Rogers SL, Farlow MR, Doody RS et al (1998) A 24-week, double-blind, placebo-controlled trial of donepezil in patients with Alzheimer's disease. Neurology 50: 136-45.
29. Burns A, Rossor M, Hecker J et al (1999) The effects of donepezil in Alzheimer's disease: results from a multinational study Dementia Geriatr Cogn Disord 10: 237-44.
30. ENA 713B303 Study Group, Rosler M, Anand R, Cicin-Sain A et al (1999) Safety and efficacy of rivastigmine in patients with Alzheimer's disease: results of an international, 26-week multicentre, randomised, placebo-controlled trial. BMJ 318: 633-8.
31. Wilcock GK, Lilienfelt S, Gaens E, on behalf of the Galanthamine International-1 study group (2000) Efficacy and safety of galanthamine in patients with mild to moderate Alzheimer's disease: multicentre randomized controlled trial. BMJ 321: 1445-9
32. Lubeck DP, Mazonson PD, Bowe T (1994) Potential effect of tacrine on expenditures for Alzheimer's disease. Med Interface 7: 130-8.
33. Henke CJ, Burchmore MJ (1997) The economic impact of tacrine in the treatment of Alzheimer's disease. Clin Ther 19: 330-45
34. Wimo A, Karlsson G, Nordberg A, Winblad B (1997) Treatment of Alzheimer's disease with tacrine: a cost-analysis model. Alzheimer's Dis Rel Disord 4: 191-200.
35. Small GW, Donohue JA, Brooks RL (1998) An economic evaluation of donepezil in the treatment of Alzheimer's disease. Clin Ther 20: 838-50.
36. Stewart A, Phillips R, Dempsey G (1998) Pharmacotherapy for people with Alzheimer's disease: a Markov-Cycle evaluation of five years' therapy using donepezil. Int j Geriatr Psychiatry 13: 445-53.
37. Jonsson L, Lindgren P, Wimo A et al (1999) The cost-effectiveness of donepezil therapy in Swedish patients with Alzheimer's disease: a Markov model. Clin Ther 21: 1230-40.
38. Neumann PJ, Hermann RC, Kuntz KM et al (1999) Cost- effectiveness of donepezil in the treatment of mild and moderate Alzheimer's disease. Neurology 52: 1138-45.
39. O'Brien BJ, Goeree R, Hux M et al (1999) Economic evaluation of donepezil for the treatment of Alzheimer's disease in Canada. J Am Geriatr Soc 47: 570-8.
40. Hauber AB, Gnanasakthy A, Snyder EH et al (2000) Potential savings in the cost of caring for Alzheimer's disease. Treatment with rivastigmine. Pharmacoeconomics 17: 351-60.
41. Hux MJ, O'Brien BJ, Iskedjian M et al (1998) Relation between severity of Alzheimer's disease and costs of caring. Can Med Assoc J 159: 457-65.
42. Ernst RL, Hay JW, Fenn C et al (1997) Cognitive function and the cost of Alzheimer's disease. An exploratory study. Arch Neurol 54: 687-93.
43. Wimo A, Witthaus K, Rother M, Winblad B (1998) Economic impact of introducing propentofylline for the treatment of dementia in Sweden. Clin Ther 20: 552-66.
44. Anonymous (2000) Alzheimer's patient still left out in the cold. Heath & Ageing October: 12-13.
45. National Institute for Clinical Excellence (2000) Guidance on use of donepezil, rivastigmine and galanthamine for the treatment of Alzheimer's disease. Technology Appraisal Guidance, No. 19. National Institute of Clinical Excellence. London.